GlaxoSmithKline (GSK plc) has received a marketing authorization from European Commission for its H5N1 adjuvanted pre-pandemic vaccine, Prepandrix, in all 27 EU member states.

GlaxoSmithKline is the first company to obtain a European license for a pre-pandemic vaccine, thereby offering European governments the potential for protecting their population in advance or at the onset of an officially declared influenza pandemic.
According to the World Health Organization (WHO), vaccines are the most important intervention for preventing influenza and reducing its health consequences during a pandemic. GlaxoSmithKline pre-pandemic H5N1 vaccine is formulated with a novel proprietary adjuvant system, which is designed to achieve a high immune response at a low dose of antigen, which is long lasting and active against a broad range of H5N1 strains.